New Delhi: Cadila Healthcare on Saturday said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine, Amlodipine, and Olmesartan Medoxomil tablets.
The nod by US Food and Drug Administration (USFDA) is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg, the company said in a BSE filing.
“The drug is indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure and will be manufactured at the group’s formulations manufacturing facility at Pharma SEZ Ahmedabad,” Cadila Healthcare added.
The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.
Latest posts by Ruby Khatun (see all)
- JnJ faulty hip implants case: CIC directs RTI disclosure of records - September 10, 2018
- Max Bupa launches WeCare initiative to aid Kerala flood victims - September 10, 2018
- Opposing Online Pharmacies, 8.5 lakh chemists to call it a strike on September 28 - September 9, 2018